W Michael Flanagan
Overview
Explore the profile of W Michael Flanagan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
336
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Ason B, Castro-Perez J, Tep S, Stefanni A, Tadin-Strapps M, Roddy T, et al.
Lipids
. 2011 Aug;
46(11):991-1003.
PMID: 21826528
The association between hypercholesterolemia and elevated serum apolipoprotein B (APOB) has generated interest in APOB as a therapeutic target for patients at risk of developing cardiovascular disease. In the clinic,...
12.
Peacock H, Fucini R, Jayalath P, Ibarra-Soza J, Haringsma H, Flanagan W, et al.
J Am Chem Soc
. 2011 May;
133(24):9200-3.
PMID: 21612237
Immune stimulation is a significant hurdle in the development of effective and safe RNA interference therapeutics. Here, we address this problem in the context of a mimic of microRNA-122 by...
13.
Wei J, Jones J, Kang J, Card A, Krimm M, Hancock P, et al.
Mol Pharmacol
. 2011 Mar;
79(6):953-63.
PMID: 21427169
Deeper knowledge of pharmacokinetic and pharmacodynamic (PK/PD) concepts for RNA therapeutics is important to streamline the drug development process and for rigorous selection of best performing drug candidates. Here we...
14.
Ason B, Tep S, Davis Jr H, Xu Y, Tetzloff G, Galinski B, et al.
J Lipid Res
. 2011 Jan;
52(4):679-87.
PMID: 21262787
Reducing circulating LDL-cholesterol (LDL-c) reduces the risk of cardiovascular disease in people with hypercholesterolemia. Current approaches to reduce circulating LDL-c include statins, which inhibit cholesterol synthesis, and ezetimibe, which blocks...
15.
Chorn G, Zhao L, Sachs A, Flanagan W, Lim L
RNA
. 2010 Oct;
16(12):2336-40.
PMID: 20971811
microRNAs are ∼ 22 nucleotide regulatory RNAs that are processed into duplexes from hairpin structures and incorporated into Argonaute proteins. Here, we show that a nick in the middle of...
16.
Kenski D, Cooper A, Li J, Willingham A, Haringsma H, Young T, et al.
Nucleic Acids Res
. 2009 Nov;
38(2):660-71.
PMID: 19917641
Small interfering RNAs (siRNAs) are short, double-stranded RNAs that use the endogenous RNAi pathway to mediate gene silencing. Phosphorylation facilitates loading of a siRNA into the Ago2 complex and subsequent...
17.
Arbitrario J, Belmont B, Evanchik M, Flanagan W, Fucini R, Hansen S, et al.
Cancer Chemother Pharmacol
. 2009 Aug;
65(4):707-17.
PMID: 19649632
Purpose: The Aurora family of serine/threonine kinases (Aurora-A, Aurora-B, and Aurora-C) plays a key role in cells orderly progression through mitosis. Elevated expression levels of Aurora kinases have been detected...
18.
Zhong M, Bui M, Shen W, Baskaran S, Allen D, Elling R, et al.
Bioorg Med Chem Lett
. 2009 Aug;
19(17):5158-61.
PMID: 19646866
This Letter describes the discovery and key structure-activity relationship (SAR) of a series of 2-aminobenzimidazoles as potent Aurora kinase inhibitors. 2-Aminobenzimidazole serves as a bioisostere of the biaryl urea residue...
19.
VanderPorten E, Taverna P, Hogan J, Ballinger M, Flanagan W, Fucini R
Mol Cancer Ther
. 2009 Apr;
8(4):930-9.
PMID: 19372566
Aurora kinases play key roles in regulating centrosome maturation, mitotic spindle formation, and cytokinesis during cell division, and are considered promising drug targets due to their frequent overexpression in a...
20.
Erlanson D, Lam J, Wiesmann C, Luong T, Simmons R, DeLano W, et al.
Nat Biotechnol
. 2003 Feb;
21(3):308-14.
PMID: 12563278
Cysteine aspartyl protease-3 (caspase-3) is a mediator of apoptosis and a therapeutic target for a wide range of diseases. Using a dynamic combinatorial technology, 'extended tethering', we identified unique nonpeptidic...